This study was inspired by the high rate (30–40%) of non-responsiveness to therapeutic anti-TNFA antibodies, which are used to treat multiple debilitating autoimmune diseases like rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. Here, TNF is linked to Crohn disease.